Anémies hémolytiques auto-immunes : diagnostic biologique et nouvelles approches thérapeutiques
| Autor: | F. Meyer, D. Rigal |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Hemolytic anemia
medicine.diagnostic_test business.industry Anemia medicine.medical_treatment Biochemistry (medical) Clinical Biochemistry Splenectomy Autoantibody Hematology medicine.disease Transplantation Coombs test hemic and lymphatic diseases Immunology Medicine Rituximab Autoimmune hemolytic anemia business medicine.drug |
| Zdroj: | Transfusion Clinique et Biologique. 18:277-285 |
| ISSN: | 1246-7820 |
| Popis: | The pattern of autoimmune hemolytic anemia has changed significantly these last 15 years. With regard to the diagnosis strategy, the use of gel filtration technique to perform the direct antiglobulin test (DAT) has decreased the number of autoimmune haemolytic anemias with negative tests results. In recent years, autoimmune haemolytic anemia increased in patients receiving purine nucleoside analogues, blood transfusions, solid organ transplantation or hematopoietic stem cells transplantation. These difficult autoimmune haemolytic anemia cases need to use new kinds of treatments. With regard to the treatment, very little progress was made this latter 50 years. The discovery of the efficacy of anti-CD20 antibody in this disease represents a breakthrough. Nowdays, the second-line treatment includes rituximab or splenectomy. Sometimes, the anti-CD20 treatment could be proposed in first-line but some clinical trials are needed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect